The serum thyrotrophin (TSH) response to thyrotrophin releasing hormone (TRH) was studied in 19 normal subjects and 60 euthyroid patients with pituitary disease. TSH was estimated by a double antibody radioimmunoassay at 0, 20 and 60 minutes after the rapid intravenous injection of TRH (200 ,ug) (Ormston et at. 1971) . All TSH levels are expressed as the mean ±1 s.d. In normal subjects the basal TSH value was 1.8 ±0.8 ,uu/ml with a range <I to 3.7 ,uu/ml, and peak values of 12.2±5.0 uu/ml were achieved at 20 minutes and fell by at least 2 ,u/ml (though not to basal values) at 60 minutes after TRH. The increment in TSH levels at 20 minutes was used as the measure of the TSH response to TRH: the normal increment was 10.4 ±4.8 ,tu/ml with a range of 4.4-23 pu/ml, responses characterized by increments of <1 pu/ml and 1-4.4 ,uu/ml being regarded as absent and partial respectively.
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Of 12 euthyroid patients with endocrineinactive pituitary tumours (largely 'chromophobe adenomas' on biopsy) only 3 (25 %) had subnormal TSH responses before treatment, the remaining 9 patients (75 %) having normal responses. In contrast, of 18 euthyroid patients with acromegaly, as many as 10 (56%) had subnormal TSH responses before treatment. Among 'Present address: c/o Ward 10 Office, Royal Victoria Infirmary, Newcastle-upon-Tyne 21 euthyroid acromegalic patients assessed three months after yttrium 90 implantation, the incidence of subnormal TSH response was as high, i.e. occurring in 67 % of patients. Among 8 euthyroid patients with endocrine-inactive tumours assessed three months after pituitary implantation, none had any impairment of TSH response. Among treated and untreated euthyroid acromegalic patients, no correlation was found between TSH responsiveness and growth hormone levels.
A normal TSH response was found in 3 out of 4 patients with Cushing's disease, 2 patients with hypothalamic disease and 2 patients with anorexia nervosa. A delayed TSH response (60 minute value > 20 minute value by at least 1 ,uu/ml) was not found, as suggested by others (Hall et al. 1972) , to be characteristic of hypothalamic disease; this pattern of response was observed in 9 subjects with various pituitary disorders and one normal subject.
Six euthyroid acromegalic patients with absent TSH responses when assessed three months after yttrium 90 implantation did not become hypothyroid during the succeeding twelve months' observation. At the three-month follow up hypothyroidism was found in 2 out of 11 acromegalics who had also been assessed before implantation, and these 2 were among the 3 who had previously normal TSH responses. A longer follow up is needed to assess the prognostic value of the TRH test in pituitary disease to be treated by yttrium 90 implants.
